Bausch Health Companies Inc. (BHC) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Bausch Health (BHC) by buying shares or fractional shares at any major US broker, through a healthcare or pharmaceutical ETF that holds it, or as one holding in a thematic basket. Bausch Health is a diversified specialty pharmaceutical company with businesses spanning gastrointestinal drugs (its Salix unit, including Xifaxan), dermatology, neurology, international pharmaceuticals, and a large majority stake in the separately listed eye-health company Bausch + Lomb. The thesis is a complex one built around a heavy debt load, the value locked in its Bausch + Lomb stake, and the durability of key products. The single biggest thing to understand is that this is a high-leverage, event-driven stock: its story revolves as much around debt reduction, litigation, patent timelines, and the potential separation of Bausch + Lomb as it does around ordinary drug sales.
BHC stock price
As of 2026-07-14, Bausch Health Companies Inc. (BHC) last closed at $4.80, down 24.3% over the past year. Over the past 52 weeks it has traded between $4.67 and $8.34.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Bausch Health Companies Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Bausch Health Companies Inc. (BHC) do?
Bausch Health Companies Inc. is a diversified specialty pharmaceutical company, formerly known as Valeant Pharmaceuticals before a 2018 rebrand. It operates across several segments: Salix (gastrointestinal, anchored by the blockbuster Xifaxan), International, Solta Medical (aesthetic devices), Diversified Products (dermatology, neurology, dentistry, and generics), and its majority ownership of Bausch + Lomb, the well-known eye-health company that trades separately. The company carries a large debt load, a legacy of its Valeant-era acquisitions, and much of the investment debate centers on how quickly it can reduce that debt and unlock value.
The 2026 picture shows an operating business that is growing while the balance sheet and legal overhang remain front and center. In the first quarter of 2026, consolidated revenue rose about 12% year over year to roughly $2.52 billion, led by strong organic growth at Salix and solid growth at Bausch + Lomb, but the company reported a large GAAP net loss driven by a roughly $1.4 billion goodwill impairment tied to a Salix program. For full-year 2026 it guided to consolidated revenue of about $10.67 to $10.92 billion. Management continues to pay down debt, and the long-planned but repeatedly delayed full separation of Bausch + Lomb, along with patent protection and litigation around Xifaxan, are the pivotal factors that will shape the stock.
What's driving Bausch Health Companies Inc. (BHC)?
1. Debt reduction and balance-sheet repair
Bausch Health carries a heavy debt load inherited from its Valeant era, and steadily reducing it is central to the equity thesis. In Q1 2026 net debt excluding Bausch + Lomb fell by roughly $115 million, and the company has been resolving litigation and generating cash to strengthen flexibility. Because the stock sits behind a large amount of debt, every dollar of deleveraging can meaningfully shift value toward equity holders.
2. Bausch + Lomb stake and potential separation
Bausch Health owns a large majority of Bausch + Lomb, the separately listed eye-health company, and the long-planned full spin-off of that stake is one of the biggest potential catalysts. Fully separating Bausch + Lomb could crystallize value and simplify the structure, though the move has been repeatedly delayed pending debt and legal conditions. The eventual outcome is a key swing factor for the stock.
3. Salix and Xifaxan durability
The Salix gastrointestinal unit, led by the blockbuster Xifaxan, is Bausch Health's most important profit driver, and it posted strong organic growth in early 2026. The durability of Xifaxan, including its patent protection and the outcome of generic-competition litigation, heavily influences future cash flow. Extending or defending that franchise is essential to the deleveraging plan.
4. Diversified specialty portfolio and Bausch + Lomb growth
Beyond Salix, Bausch Health spans dermatology, neurology, international pharmaceuticals, and aesthetics, while the consolidated Bausch + Lomb eye-health business continues to grow organically. This breadth spreads risk across multiple therapeutic areas and geographies, so no single product loss is fatal, and steady eye-health growth supports overall revenue even as individual drugs face pressure.
What are the risks to Bausch Health Companies Inc. (BHC)?
The dominant risk is leverage: Bausch Health's large debt load makes the equity a leveraged claim, so weak cash flow, higher interest rates, or refinancing trouble can sharply pressure the stock. The Xifaxan franchise is a concentration risk; loss of patent protection or an adverse outcome in generic-competition litigation would hit a major profit source. The Bausch + Lomb separation has been delayed repeatedly and remains uncertain, so the value-unlock catalyst may not arrive on the timeline investors hope. Bausch Health also carries legacy legal and reputational overhang from its Valeant past, and it took a roughly $1.4 billion goodwill impairment in Q1 2026, a reminder that reported results can be volatile. Ordinary pharma risks apply too: pipeline setbacks, pricing and regulatory pressure, and generic erosion across the diversified portfolio. This is an event-driven, higher-risk name whose value depends on execution across debt, legal, and corporate-structure fronts.
How is Bausch Health Companies Inc. (BHC) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bausch Health Companies Inc.'s investor relations page or your broker.
- Business model: Diversified specialty pharma (Salix, International, dermatology, neurology, aesthetics) plus a majority stake in Bausch + Lomb eye health
- Recent results: Q1 2026 consolidated revenue up ~12% year over year to roughly $2.52 billion, led by Salix
- Reported loss: Large GAAP net loss in Q1 2026 driven by a ~$1.4 billion goodwill impairment tied to a Salix program
- Full-year guidance: Consolidated 2026 revenue of about $10.67 to $10.92 billion
- Balance sheet: Carries a heavy debt load; net debt excluding Bausch + Lomb fell modestly in Q1 2026
- Key catalyst: The long-delayed full separation of the Bausch + Lomb stake
Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Bausch Health is heavily indebted, traditional earnings multiples matter less than enterprise value, debt trajectory, and the value of the Bausch + Lomb stake. Reported GAAP results can swing on non-cash items like the Q1 2026 impairment, so focus on cash generation, deleveraging, and the durability of Xifaxan rather than a single headline number.
Who competes with Bausch Health Companies Inc. (BHC)?
Specialty and diversified pharma
Companies like Jazz Pharmaceuticals, Organon, Viatris, and other diversified specialty drugmakers compete across gastrointestinal, dermatology, and neurology categories. Like Bausch Health, several carry meaningful debt and manage portfolios of mature and specialty products, so they share a similar risk-and-cash-flow profile.
Eye health and Bausch + Lomb rivals
Through its Bausch + Lomb stake, Bausch Health competes in eye health against Alcon, Johnson & Johnson's vision business, and CooperCompanies in contact lenses, surgical, and consumer eye-care products. These rivals shape the value of the Bausch + Lomb business that is central to Bausch Health's thesis.
Generic and biosimilar competitors
Generic-drug makers such as Teva and Sandoz, and generic challengers to Xifaxan specifically, threaten Bausch Health's branded franchises once patents expire or litigation concludes. Generic erosion is a constant force across its diversified portfolio and a key determinant of long-term cash flow.
How to invest in Bausch Health Companies Inc. (BHC)
There are three common ways to get BHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BHC sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where BHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Bausch Health Companies Inc. (BHC)
Bausch Health is a highly leveraged specialty pharma whose story hinges on debt reduction, the value of its majority stake in Bausch + Lomb, and the durability of key drugs like Xifaxan, making it an event-driven, higher-risk name rather than a steady healthcare compounder.
Build a basket around BHC with Walnut
Use Bausch Health Companies Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BHC a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a growing operating business, ongoing debt reduction, the durable Salix franchise, and potential value from separating Bausch + Lomb. The bear case is a heavy debt load, concentration risk in Xifaxan, repeated delays to the Bausch + Lomb spin-off, and legacy legal overhang. This is an event-driven, higher-risk name; weigh both against your portfolio.
What does Bausch Health actually do?
+
Bausch Health is a diversified specialty pharmaceutical company with businesses in gastrointestinal drugs (Salix, including Xifaxan), dermatology, neurology, aesthetics, and international pharmaceuticals, plus a majority stake in the separately listed eye-health company Bausch + Lomb. It was formerly known as Valeant Pharmaceuticals before rebranding in 2018.
Why is Bausch Health's debt so important to the stock?
+
Bausch Health carries a large debt load from its Valeant-era acquisitions, which makes its equity a leveraged claim on the business. As debt falls, more value can flow to shareholders, but heavy leverage also magnifies risk if cash flow weakens or refinancing gets harder. That is why deleveraging progress is a central focus for investors.
What is the Bausch + Lomb separation?
+
Bausch Health owns a majority of Bausch + Lomb, a separately listed eye-health company, and has long planned to fully spin off that stake to unlock value and simplify its structure. The full separation has been repeatedly delayed pending debt and legal conditions, and its eventual completion is one of the biggest potential catalysts for the stock.
How important is Xifaxan to Bausch Health?
+
Very. Xifaxan, sold through the Salix unit, is Bausch Health's most important product and a major profit driver. Its future cash flow depends on patent protection and the outcome of generic-competition litigation. Any loss of exclusivity or adverse legal ruling would materially affect earnings and the company's ability to reduce debt.
Does Bausch Health pay a dividend?
+
Bausch Health has generally prioritized paying down debt over returning cash to shareholders, so it is not primarily an income stock. Any capital-return policy can change with its balance-sheet progress. Always check the company's latest disclosures before assuming any dividend or buyback.
How can I get exposure to Bausch Health through an ETF?
+
BHC appears in various healthcare and pharmaceutical ETFs, typically at a small weighting given its size and risk profile. ETF exposure spreads single-stock risk across many holdings but dilutes how much any Bausch Health move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Bausch Health specifically.
What are the main risks of investing in BHC?
+
The biggest risk is heavy leverage, which magnifies the impact of weak cash flow or refinancing trouble. Add concentration in Xifaxan and its patent and litigation risk, repeated delays to the Bausch + Lomb spin-off, legacy legal overhang from the Valeant era, and ordinary pharma risks like generic erosion and pricing pressure. Reported results can also swing on non-cash charges.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Bausch Health Companies Inc.'s investor relations page or your broker before making investment decisions.